amfetamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
anorexics	195	300-62-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: amphetamine aspartate monohydrate benzadrine amphetamine adderall 1-Benzylethylamine phenedrine (+/-)-1-Phenyl-2-aminopropane amfetamine amphetamine sulfate amphetamine aspartate amphetamine adipate amphetamine resin complex	A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE. Molecular weight: 135.21 Formula: C9H13N CLOGP: 1.74 LIPINSKI: 0 HAC: 1 HDO: 1 TPSA: 26.02 ALOGS: -1.89 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

amphetamine aspartate monohydrate
benzadrine
amphetamine
adderall
1-Benzylethylamine
phenedrine
(+/-)-1-Phenyl-2-aminopropane
amfetamine
amphetamine sulfate
amphetamine aspartate
amphetamine adipate
amphetamine resin complex

A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.

Molecular weight: 135.21
Formula: C9H13N
CLOGP: 1.74
LIPINSKI: 0
HAC: 1
HDO: 1
TPSA: 26.02
ALOGS: -1.89
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
15	mg	O
15	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	0	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	30 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	40 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	7.40 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	6.10 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	9.70 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.80 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	7.30 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Sept. 9, 1955	FDA	UCB INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Toxicity to various agents	858.67	21.07	442	5636	212057	50386989
Completed suicide	806.21	21.07	365	5713	131524	50467522
Drug abuse	740.39	21.07	275	5803	59571	50539475
Cardio-respiratory arrest	270.75	21.07	131	5947	53761	50545285
Respiratory arrest	226.71	21.07	97	5981	29912	50569134
Cardiac arrest	176.29	21.07	115	5963	83536	50515510
Poisoning	148.72	21.07	56	6022	12373	50586673
Coronary artery dissection	94.26	21.07	21	6057	706	50598340
Overdose	92.02	21.07	84	5994	99643	50499403
Exposure via ingestion	66.17	21.07	21	6057	2782	50596264
Renal infarct	62.15	21.07	17	6061	1343	50597703
Death	55.39	21.07	121	5957	325258	50273788
Intentional product misuse	46.24	21.07	41	6037	46693	50552353
Accidental overdose	38.93	21.07	26	6052	19507	50579539
Intestinal infarction	38.69	21.07	11	6067	1001	50598045
Product substitution issue	33.66	21.07	21	6057	14036	50585010
Substance abuse	33.29	21.07	14	6064	4110	50594936
Agitation	32.60	21.07	36	6042	53348	50545698
Brain oedema	28.41	21.07	18	6060	12352	50586694
Serotonin syndrome	25.07	21.07	22	6056	24691	50574355
Arteritis infective	22.09	21.07	4	6074	45	50599001
Intentional overdose	21.95	21.07	32	6046	62472	50536574
Tachycardia	21.49	21.07	41	6037	99722	50499324
Hepatic necrosis	21.09	21.07	11	6067	5237	50593809

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug abuse	1618.67	29.81	624	6214	79259	29488430
Toxicity to various agents	1597.45	29.81	774	6064	172887	29394802
Completed suicide	433.82	29.81	265	6573	89981	29477708
Respiratory arrest	283.76	29.81	132	6706	25701	29541988
Cardio-respiratory arrest	227.94	29.81	143	6695	50458	29517231
Cardiac arrest	204.14	29.81	164	6674	85427	29482262
Poisoning	178.29	29.81	72	6766	9921	29557768
Overdose	125.76	29.81	121	6717	79698	29487991
Brain oedema	120.31	29.81	58	6780	12162	29555527
Intentional product misuse	117.11	29.81	82	6756	34579	29533110
Decreased eye contact	110.33	29.81	25	6813	460	29567229
Oppositional defiant disorder	108.08	29.81	25	6813	506	29567183
Respiratory depression	97.49	29.81	52	6786	13471	29554218
Pulmonary oedema	95.46	29.81	79	6759	42656	29525033
Bruxism	89.48	29.81	27	6811	1560	29566129
Drug dependence	88.49	29.81	57	6781	20924	29546765
Substance abuse	84.77	29.81	38	6800	6749	29560940
Homicidal ideation	77.16	29.81	27	6811	2497	29565192
Aggression	73.76	29.81	63	6775	35478	29532211
Crying	66.95	29.81	30	6808	5321	29562368
Internal injury	58.32	29.81	9	6829	13	29567676
Choreoathetosis	55.98	29.81	17	6821	1003	29566686
Exposure via ingestion	55.66	29.81	20	6818	1998	29565691
Dyskinesia	53.08	29.81	41	6797	20020	29547669
Trismus	48.92	29.81	19	6819	2354	29565335
Suicidal ideation	45.99	29.81	48	6790	34668	29533021
Coordination abnormal	44.72	29.81	25	6813	7089	29560600
Hyperkinesia	44.67	29.81	16	6822	1583	29566106
Accidental overdose	44.47	29.81	35	6803	17558	29550131
Vertebral artery dissection	39.25	29.81	7	6831	34	29567655
Affect lability	39.16	29.81	18	6820	3384	29564305
Stress cardiomyopathy	37.05	29.81	14	6824	1610	29566079
Asphyxia	37.05	29.81	20	6818	5295	29562394
Psychomotor hyperactivity	36.30	29.81	23	6815	8190	29559499
Diarrhoea	34.53	29.81	17	6821	332681	29235008
Streptococcal infection	34.42	29.81	18	6820	4470	29563219
Pulmonary congestion	34.16	29.81	26	6812	12410	29555279
Mood altered	34.07	29.81	22	6816	8089	29559600
Poor quality sleep	33.84	29.81	21	6817	7212	29560477
Irritability	33.66	29.81	33	6805	22119	29545570
Dyspnoea	33.44	29.81	17	6821	326715	29240974
Spinal shock	33.01	29.81	6	6832	33	29567656
Cluster headache	30.57	29.81	9	6829	477	29567212
Anaemia	30.44	29.81	5	6833	200946	29366743
Amphetamines positive	29.87	29.81	7	6831	150	29567539

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug abuse	2321.61	22.80	869	10612	131505	64355746
Toxicity to various agents	2307.14	22.80	1160	10321	362353	64124898
Completed suicide	1168.71	22.80	632	10849	223782	64263469
Respiratory arrest	522.63	22.80	232	11249	52753	64434498
Cardio-respiratory arrest	508.27	22.80	277	11204	98116	64389135
Cardiac arrest	389.09	22.80	275	11206	153789	64333462
Poisoning	316.61	22.80	126	11355	21753	64465498
Overdose	202.57	22.80	191	11290	159375	64327876
Intentional product misuse	145.81	22.80	113	11368	72182	64415069
Brain oedema	124.29	22.80	66	11415	22009	64465242
Substance abuse	118.79	22.80	49	11432	9243	64478008
Exposure via ingestion	117.79	22.80	41	11440	4861	64482390
Oppositional defiant disorder	116.77	22.80	25	11456	461	64486790
Coronary artery dissection	106.23	22.80	26	11455	884	64486367
Decreased eye contact	105.48	22.80	25	11456	740	64486511
Respiratory depression	101.59	22.80	59	11422	23384	64463867
Accidental overdose	89.18	22.80	62	11419	33495	64453756
Drug dependence	87.25	22.80	61	11420	33251	64454000
Death	86.31	22.80	233	11248	482472	64004779
Pulmonary oedema	80.70	22.80	84	11397	78590	64408661
Bruxism	78.25	22.80	28	11453	3596	64483655
Aggression	77.70	22.80	65	11416	46167	64441084
Homicidal ideation	73.49	22.80	26	11455	3231	64484020
Diarrhoea	52.53	22.80	32	11449	722672	63764579
Choreoathetosis	46.24	22.80	15	11466	1432	64485819
Renal infarct	45.99	22.80	17	11464	2394	64484857
Serotonin syndrome	45.84	22.80	45	11436	39237	64448014
Dyskinesia	45.74	22.80	45	11436	39343	64447908
Internal injury	45.40	22.80	11	11470	358	64486893
Amphetamines positive	44.56	22.80	10	11471	231	64487020
Unresponsive to stimuli	43.24	22.80	49	11432	50344	64436907
Pulmonary congestion	43.08	22.80	35	11446	23845	64463406
Anaemia	42.51	22.80	8	11473	378672	64108579
Intentional overdose	42.19	22.80	65	11416	89879	64397372
Hyperkinesia	41.49	22.80	16	11465	2530	64484721
Dyspnoea	40.61	22.80	41	11440	718633	63768618
Trismus	40.43	22.80	19	11462	4882	64482369
Suicidal ideation	39.85	22.80	54	11427	66488	64420763
Affect lability	37.28	22.80	22	11459	8968	64478283
Miosis	36.37	22.80	25	11456	13241	64474010
Pneumonia	36.30	22.80	28	11453	559548	63927703
Coordination abnormal	35.93	22.80	26	11455	14938	64472313
Irritability	35.45	22.80	38	11443	36708	64450543
Crying	35.30	22.80	29	11452	20061	64467190
Agitation	33.49	22.80	58	11423	88309	64398942
Asphyxia	33.48	22.80	21	11460	9545	64477706
Pyrexia	32.51	22.80	31	11450	558613	63928638
Psychomotor hyperactivity	32.19	22.80	24	11457	14427	64472824
Drug screen positive	31.86	22.80	17	11464	5712	64481539
Product substitution issue	31.84	22.80	26	11455	17835	64469416
Intestinal infarction	31.79	22.80	11	11470	1280	64485971
Streptococcal infection	30.22	22.80	18	11463	7461	64479790
Vertebral artery dissection	29.16	22.80	7	11474	219	64487032
Drug use disorder	28.25	22.80	16	11465	6038	64481213
Cluster headache	27.90	22.80	9	11472	844	64486407
Substance use disorder	25.79	22.80	7	11474	360	64486891
Suspected suicide	25.37	22.80	17	11464	8637	64478614
Vomiting	25.19	22.80	37	11444	551080	63936171
Rash	24.88	22.80	27	11454	458522	64028729
Rhabdomyolysis	24.62	22.80	52	11429	91674	64395577
Stress cardiomyopathy	24.33	22.80	17	11464	9240	64478011
Mood altered	23.84	22.80	21	11460	15958	64471293
Accidental death	23.42	22.80	12	11469	3713	64483538
Anxiety	23.18	22.80	84	11397	202565	64284686
Physical abuse	23.05	22.80	4	11477	22	64487229
Off label use	23.03	22.80	49	11432	632757	63854494
Malaise	23.01	22.80	22	11459	396225	64091026

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N06BA01	NERVOUS SYSTEM PSYCHOANALEPTICS PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS Centrally acting sympathomimetics
CHEBI has role	CHEBI:35523	bronchodilator
CHEBI has role	CHEBI:35524	sympathomimetic
CHEBI has role	CHEBI:35640	adrenergic uptake inhibitors
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:37962	adrenergic agents
CHEBI has role	CHEBI:48560	dopaminergic agents
CHEBI has role	CHEBI:50910	agente neurotoxico
CHEBI has role	CHEBI:51039	dopamine reuptake inhibitor
CHEBI has role	CHEBI:78298	environmental contaminants
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D000697	Central Nervous System Stimulants
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D018759	Adrenergic Uptake Inhibitors
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018765	Dopamine Uptake Inhibitors
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D013566	Sympathomimetics
FDA PE	N0000175729	Central Nervous System Stimulation
FDA EPC	N0000175739	Central Nervous System Stimulant

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Narcolepsy	indication	60380001	DOID:8986
Attention deficit hyperactivity disorder	indication	406506008
Obesity	indication	414916001	DOID:9970
Ocular hypertension	contraindication	4210003	DOID:9282
Gilles de la Tourette's syndrome	contraindication	5158005	DOID:11119
Suicidal thoughts	contraindication	6471006
Dependent drug abuse	contraindication	6525002
Alcoholism	contraindication	7200002
Hyperammonemia	contraindication	9360008
Chronic obstructive lung disease	contraindication	13645005	DOID:3083
Bipolar disorder	contraindication	13746004	DOID:3312
Hepatic encephalopathy	contraindication	13920009	DOID:13413
Myocardial infarction	contraindication	22298006	DOID:5844
Glaucoma	contraindication	23986001	DOID:1686
Feeling agitated	contraindication	24199005
Hyperthyroidism	contraindication	34486009	DOID:7998
Depressive disorder	contraindication	35489007
Hypertensive disorder	contraindication	38341003	DOID:10763
Hyperactive behavior	contraindication	44548000
Conduction disorder of the heart	contraindication	44808001
Chronic heart failure	contraindication	48447003
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Anorexia nervosa	contraindication	56882008	DOID:8689
Hepatic failure	contraindication	59927004
Aggressive behavior	contraindication	61372001
Substance abuse	contraindication	66214007
Psychotic disorder	contraindication	69322001
Arteriosclerotic vascular disease	contraindication	72092001
Hepatic coma	contraindication	72836002	DOID:12550
Diabetes mellitus	contraindication	73211009	DOID:9351
Sleep apnea	contraindication	73430006	DOID:0050847
Open-angle glaucoma	contraindication	84494001	DOID:1067
Cardiomyopathy	contraindication	85898001	DOID:0050700
Weight loss	contraindication	89362005
Kidney disease	contraindication	90708001	DOID:557
Structural disorder of heart	contraindication	128599005
Seizure disorder	contraindication	128613002
Motor tic disorder	contraindication	230337001
Cerebrovascular accident	contraindication	230690007
Mania	contraindication	231494001
Disease of liver	contraindication	235856003	DOID:409
Sleep automatism	contraindication	247962006
Anemia	contraindication	271737000	DOID:2355
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Cardiovascular event risk	contraindication	395112001
Visual impairment	contraindication	397540003
Respiratory insufficiency	contraindication	409623005
Breastfeeding (mother)	contraindication	413712001
Disorder of coronary artery	contraindication	414024009
Myocardial ischemia	contraindication	414795007	DOID:3393
Myocardial infarction in recovery phase	contraindication	418044006
Porphyria	contraindication	418470004
Hypertensive urgency	contraindication	443482000
Acute exacerbation of asthma	contraindication	708038006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.89	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
12.5MG;12.5MG;12.5MG;12.5MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	6913768	May 24, 2023	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
3.125MG;3.125MG;3.125MG;3.125MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	6913768	May 24, 2023	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
6.25MG;6.25MG;6.25MG;6.25MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	6913768	May 24, 2023	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
9.375MG;9.375MG;9.375MG;9.375MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	6913768	May 24, 2023	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
12.5MG;12.5MG;12.5MG;12.5MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	9173857	May 12, 2026	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
3.125MG;3.125MG;3.125MG;3.125MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	9173857	May 12, 2026	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
6.25MG;6.25MG;6.25MG;6.25MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	9173857	May 12, 2026	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
9.375MG;9.375MG;9.375MG;9.375MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	9173857	May 12, 2026	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
12.5MG;12.5MG;12.5MG;12.5MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	Sept. 13, 2022	INFORMATION ADDED TO THE LABELING TO DESCRIBE A TRIAL EVALUATING A LOWER DOSE THAN THOSE APPROVED FOR PEDIATRIC PATIENTS 13 TO 17 YEARS OF AGE
3.125MG;3.125MG;3.125MG;3.125MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	Sept. 13, 2022	INFORMATION ADDED TO THE LABELING TO DESCRIBE A TRIAL EVALUATING A LOWER DOSE THAN THOSE APPROVED FOR PEDIATRIC PATIENTS 13 TO 17 YEARS OF AGE
6.25MG;6.25MG;6.25MG;6.25MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	Sept. 13, 2022	INFORMATION ADDED TO THE LABELING TO DESCRIBE A TRIAL EVALUATING A LOWER DOSE THAN THOSE APPROVED FOR PEDIATRIC PATIENTS 13 TO 17 YEARS OF AGE
9.375MG;9.375MG;9.375MG;9.375MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	Sept. 13, 2022	INFORMATION ADDED TO THE LABELING TO DESCRIBE A TRIAL EVALUATING A LOWER DOSE THAN THOSE APPROVED FOR PEDIATRIC PATIENTS 13 TO 17 YEARS OF AGE
12.5MG;12.5MG;12.5MG;12.5MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	March 13, 2023	PEDIATRIC EXCLUSIVITY
3.125MG;3.125MG;3.125MG;3.125MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	March 13, 2023	PEDIATRIC EXCLUSIVITY
6.25MG;6.25MG;6.25MG;6.25MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	March 13, 2023	PEDIATRIC EXCLUSIVITY
9.375MG;9.375MG;9.375MG;9.375MG	MYDAYIS	TAKEDA PHARMS USA	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	March 13, 2023	PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN	RELEASING AGENT	Ki	6.94	PDSP	CHEMBL
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	RELEASING AGENT			CHEMBL	CHEMBL
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN				WOMBAT-PK
Cocaine- and amphetamine-regulated transcript protein	Transcription factor	Q16568	CART_HUMAN				WOMBAT-PK
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN				WOMBAT-PK
Trace amine-associated receptor 1	GPCR	Q96RJ0	TAAR1_HUMAN	AGONIST	EC50	6.22	SCIENTIFIC LITERATURE
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	5.75	PDSP
Sodium-dependent dopamine transporter	Transporter		SC6A3_RAT		IC50	6.02	CHEMBL
Amine oxidase [flavin-containing] A	Enzyme		AOFA_RAT		Ki	4.91	CHEMBL
Sodium-dependent noradrenaline transporter	Transporter		SC6A2_MOUSE		IC50	6	CHEMBL
5-hydroxytryptamine receptor 2B	GPCR		5HT2B_RAT		Kd	5.27	CHEMBL
Sodium-dependent serotonin transporter	Transporter		SC6A4_MOUSE		IC50	4.35	CHEMBL
Transporter	Transporter		Q63380_RAT		IC50	6.70	CHEMBL
Serotonin (5-HT) receptor	GPCR		5HT2C_RAT 5HT2A_RAT 5HT1A_RAT 5HT1B_RAT 5HT1D_RAT 5HT1F_RAT 5HT2B_RAT 5HT6R_RAT 5HT7R_RAT 5HT5A_RAT 5HT5B_RAT 5HT3A_RAT 5HT4R_RAT 5HT3B_RAT		Kd	5.27	CHEMBL
Serotonin 1 (5-HT1) receptor	GPCR		5HT1A_RAT 5HT1B_RAT 5HT1D_RAT 5HT1F_RAT		Ki	5.12	CHEMBL
Serotonin 2 (5-HT2) receptor	GPCR		5HT2C_RAT 5HT2A_RAT 5HT2B_RAT		Ki	4.37	CHEMBL

External reference:

ID	Source
4019611	VUID
N0000147705	NUI
D02074	KEGG_DRUG
851591-76-9	SECONDARY_CAS_RN
60-13-9	SECONDARY_CAS_RN
25333-81-7	SECONDARY_CAS_RN
64770-51-0	SECONDARY_CAS_RN
221057	RXNORM
C0002658	UMLSCUI
CHEBI:2679	CHEBI
CHEMBL405	ChEMBL_ID
CHEMBL501	ChEMBL_ID
CHEMBL1200377	ChEMBL_ID
DB00182	DRUGBANK_ID
C090411	MESH_SUPPLEMENTAL_RECORD_UI
4804	IUPHAR_LIGAND_ID
O1ZPV620O4	UNII
3007	PUBCHEM_CID
290726	MMSL
31375	MMSL
4188	MMSL
4189	MMSL
6025	MMSL
d00803	MMSL
001790	NDDF
001791	NDDF
001792	NDDF
006719	NDDF
4018832	VANDF
4018833	VANDF
4018834	VANDF
4019611	VANDF
4022215	VANDF
D000661	MESH_DESCRIPTOR_UI
CHEMBL1200387	ChEMBL_ID
377	INN_ID
116344009	SNOMEDCT_US
22672005	SNOMEDCT_US
703842006	SNOMEDCT_US
87148003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1328	CAPSULE, EXTENDED RELEASE	1.25 mg	ORAL	NDA AUTHORIZED GENERIC	36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1328	CAPSULE, EXTENDED RELEASE	1.25 mg	ORAL	NDA AUTHORIZED GENERIC	36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1329	CAPSULE, EXTENDED RELEASE	2.50 mg	ORAL	NDA AUTHORIZED GENERIC	36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1329	CAPSULE, EXTENDED RELEASE	2.50 mg	ORAL	NDA AUTHORIZED GENERIC	36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1330	CAPSULE, EXTENDED RELEASE	3.75 mg	ORAL	NDA AUTHORIZED GENERIC	36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1330	CAPSULE, EXTENDED RELEASE	3.75 mg	ORAL	NDA AUTHORIZED GENERIC	36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1331	CAPSULE, EXTENDED RELEASE	5 mg	ORAL	NDA AUTHORIZED GENERIC	36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1331	CAPSULE, EXTENDED RELEASE	5 mg	ORAL	NDA AUTHORIZED GENERIC	36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1332	CAPSULE, EXTENDED RELEASE	6.25 mg	ORAL	NDA AUTHORIZED GENERIC	36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1332	CAPSULE, EXTENDED RELEASE	6.25 mg	ORAL	NDA AUTHORIZED GENERIC	36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1333	CAPSULE, EXTENDED RELEASE	7.50 mg	ORAL	NDA AUTHORIZED GENERIC	36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1333	CAPSULE, EXTENDED RELEASE	7.50 mg	ORAL	NDA AUTHORIZED GENERIC	36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1486	CAPSULE	1.25 mg	ORAL	ANDA	28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1486	CAPSULE	1.25 mg	ORAL	ANDA	28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1487	CAPSULE	2.50 mg	ORAL	ANDA	28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1487	CAPSULE	2.50 mg	ORAL	ANDA	28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1488	CAPSULE	3.75 mg	ORAL	ANDA	28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1488	CAPSULE	3.75 mg	ORAL	ANDA	28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1489	CAPSULE	5 mg	ORAL	ANDA	28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1489	CAPSULE	5 mg	ORAL	ANDA	28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1490	CAPSULE	6.25 mg	ORAL	ANDA	28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1490	CAPSULE	6.25 mg	ORAL	ANDA	28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1491	CAPSULE	7.50 mg	ORAL	ANDA	28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1491	CAPSULE	7.50 mg	ORAL	ANDA	28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0185-0831	TABLET	1.25 mg	ORAL	ANDA	21 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0185-0831	TABLET	1.25 mg	ORAL	ANDA	21 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0185-0831	TABLET	1.25 mg	ORAL	ANDA	21 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0185-0831	TABLET	1.25 mg	ORAL	ANDA	21 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0185-0842	TABLET	2.50 mg	ORAL	ANDA	21 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0185-0842	TABLET	2.50 mg	ORAL	ANDA	21 sections